Stevanato Group reported a 9% increase in revenue for the first quarter of 2025, reaching €256.6 million, primarily driven by strong performance in the Biopharmaceutical and Diagnostic Solutions segment. Gross profit and operating profit margins also improved. The company maintained its full-year revenue guidance but lowered its adjusted EBITDA and adjusted diluted EPS guidance to reflect the estimated impact of recently announced tariffs.
Revenue increased by 9% to €256.6 million in Q1 2025 compared to the prior year.
The Biopharmaceutical and Diagnostic Solutions segment saw 11% revenue growth, offsetting a decline in the Engineering segment.
Gross profit margin improved by 80 basis points to 27.2%, and adjusted operating profit margin increased to 14.3%.
Full-year 2025 guidance for adjusted EBITDA and adjusted diluted EPS was updated to reflect the estimated impact of tariffs.
For fiscal year 2025, Stevanato Group maintains its revenue guidance of €1,160 million to €1,190 million. However, guidance for adjusted EBITDA is updated to €288.5 million to €301.8 million, and adjusted diluted EPS to €0.50 to €0.54, reflecting an estimated €4.5 million tariff impact on operating profit.
Visualization of income flow from segment revenue to net income